Aimmune Therapeutics
NEWS
It was a busy week for clinical trial updates for the first week of November. Here’s a look.
AR101 is an investigational, peanut-derived, biologic drug candidate for oral immunotherapy in patients with peanut allergy. It delivers a daily dose of peanut protein with a consistent protein profile.
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Immunology (ACAAI).
Aimmune’s peanut allergy treatment is one-step closer to approval following strong support from the Allergenic Products Advisory Committee, which overwhelmingly recommended approval of Palforzia, the proposed trade name of the investigational oral treatment, AR101.
Companies from across the globe provide information on agreements and pipeline updates.
The add-on data showed that longer treatment with AR101 provided higher tolerance levels to peanut protein.
With the ever-rising concerns over the costs of various prescription medications, a report from consumer pharmaceutical watchdog group Institute for Clinical and Economic Review released a report questioning the potential pricing of two yet-to-be-approved peanut allergy treatments.
Brisbane, Calif.-based Aimmune Therapeutics announced that its Phase III European clinical trial of AR101 for treatment of peanut allergy met its primary efficacy endpoint.
When it comes to biotech and pharma innovation few places stand out like the Biotech Bay. The area is home to a plethora of innovative companies that are shaping the future of medical treatment for a variety of diseases and conditions on a daily basis.
JOBS
IN THE PRESS